Sign In
Buy AVTX
$18.25
-1.14 (-5.88%)
At Close: Jul 31, 2026
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
11:01am, Thursday, 02'nd Apr 2026
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
07:00am, Monday, 23'rd Mar 2026
WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for i
Ally Bridge Group NY LLC Purchases New Position in Avalo Therapeutics, Inc. $AVTX
03:31am, Sunday, 15'th Mar 2026
Ally Bridge Group NY LLC acquired a new position in Avalo Therapeutics, Inc. (NASDAQ: AVTX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. T
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference
01:14am, Saturday, 14'th Mar 2026
Avalo Therapeutics (NASDAQ: AVTX) CEO Garry Neil said the company expects to report top-line data in the second quarter from its completed Phase 2b LOTUS trial of AVTX-009 in hidradenitis suppurativa
Silence Therapeutics (NASDAQ:SLN) versus Avalo Therapeutics (NASDAQ:AVTX) Head-To-Head Comparison
04:26am, Wednesday, 11'th Mar 2026
Avalo Therapeutics (NASDAQ: AVTX - Get Free Report) and Silence Therapeutics (NASDAQ: SLN - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the
Avalo Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Tuesday, 24'th Feb 2026
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 18'th Feb 2026
WAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Price Target at $34.88
01:58am, Monday, 16'th Feb 2026
Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven research firms that are currently covering the stock, Marketbeat Rating
Avalo Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 04'th Feb 2026
WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case
02:25pm, Monday, 02'nd Feb 2026
Avalo Therapeutics Inc.'s (NASDAQ: AVTX) completed enrollment of the Phase 2 LOTUS trial of AVTX-009, the company's lead drug candidate.
Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $32.71 Consensus Price Target from Analysts
01:31am, Thursday, 22'nd Jan 2026
Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. On
Reviewing Avalo Therapeutics (NASDAQ:AVTX) and Aditxt (NASDAQ:ADTX)
01:24am, Sunday, 11'th Jan 2026
Aditxt (NASDAQ: ADTX - Get Free Report) and Avalo Therapeutics (NASDAQ: AVTX - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two compa
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Monday, 17'th Nov 2025
WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
07:00am, Thursday, 06'th Nov 2025
Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026 Appointed Kevin Lind to Board of Directors Expanded leadership tea
Avalo Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Monday, 03'rd Nov 2025
WAYNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated
